

Covid-19, Viral Vector & DNA and mRNA Based Vaccines Catapults the Billion Dollar Vaccine Market

Viral vector, nucleic acid-based vaccines, fast-growing Shingles, Varicella & IPV vaccines and combination vaccines key drivers of global vaccines market

PORTLAND, OREGON, UNITED STATES, September 24, 2021 /

[EINPresswire.com/](https://www.einpresswire.com/) -- The [Global Vaccines Market](#) is expected to clock

US\$ ~93.17 billion by 2031 owing to technological advancements such as viral vector and nucleic acid-based vaccines (DNA and mRNA vaccines), fast-growing Shingles, Varicella & IPV vaccines, rising birth rate, outbreak of several vaccine preventable diseases, rising adoption of combination vaccines, robust product pipeline of key players and growing government initiatives for immunization programmes.

Clairvoyance Research conducted an in-depth market analysis study of the global vaccines market. The study comprehensively analyzes the market from different perspectives and provides granular insights on hot revenue pockets, headwinds & tailwinds impacting the market, quantitative (market size & forecasts) and qualitative analysis from 'Patient Type, Strain Type, Technology, Vaccine Type, Route of Administration and Region' perspective, product pipeline, and competitive landscape.

[Access 'Sample Pages' of the Report](#)

Key Market Trends

The ongoing pandemic of COVID-19 has affected almost every country worldwide, and resulted in severe outcomes, across all these regions. Several organizations and prominent players are



CLAIRVOYANCE RESEARCH
BENCHTRENDING COMPETITION.ACCEPTING GROWTH



Vaccine - Savior of Mankind

making collaborative efforts to provide vaccines to different countries and to help them address new challenges by guaranteeing the continuous & efficient supply of COVID-19 vaccines in priority areas. Incessantly rising number of people infected with COVID-19, favorable funding's & incentives from global governments and foundations for vaccine development and promising R&D landscape for COVID-19 vaccines are some of the pivotal factors which are expected to bolster its demand in the coming months/years. Currently, R&D landscape for COVID-19 vaccines includes 115 vaccine candidates. Global organizations/foundations such as WHO, CEPI, WHO, Bill and Melinda Gates Foundation are also increasingly providing incentives to vaccine manufacturers for large-scale production of SARS-CoV-2 vaccines. COVID-19 Vaccines Global Access (COVAX), a worldwide initiative aimed at equitable access to COVID-19 vaccines, co-led by CEPI, Gavi and WHO, alongside key delivery partner UNICEF has also played an instrumental role in driving the global COVID-19 vaccines market.

The global vaccines market has been analyzed from six different perspectives – Patient Type, Strain Type, Technology, Vaccine Type, Route of Administration and Region.

Key Takeaways – Vaccine Type Perspective

PCV, D&T-containing, HPV and influenza vaccines generate the highest market value while new vaccines such as Shingles, Varicella, IPV are expected to propel the market growth in the coming years. Technological advancements such as mRNA and vector vaccines, continuously rising prevalence of infectious diseases, rising government focus on immunization programs and robust product pipeline are some of the key factors that are expected to drive the demand of vaccines globally.

Key Takeaways – Technology Perspective

Recombinant vaccines segment is expected to be the fastest growing segment in the market during the forecast period. The growth of the segment can be mainly attributed to development and launch of several recombinant vaccines.

Snapshot - Competitive Landscape

The vaccines market is marked by presence of prominent players such as Merck & Co., Sanofi, GlaxoSmithKline plc., Pfizer Inc., AstraZeneca, CSL Limited, Panacea Biotec Ltd., Serum Institute of India Pvt. Ltd., PT Bio Farma (Persero), Bavarian Nordic, among others. Other players operating in the market are Bharat Biotech, Emergent BioSolutions Inc., Johnson & Johnson Private Limited, Mitsubishi Tanabe Pharma Corporation, among others.

[For deep-rooted insights, please explore the Report](#)

NEED MORE?

Talk to us about your requirements and get a customized report

Get more details about the content of report

Request 'Sample Pages' of the report

Vinit Singh

Clairvoyance Research

+91 8761988338

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/552208376>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.